Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
RaySearch Laboratories AB ( ($SE:RAY.B) ) has issued an announcement.
RaySearch Laboratories has secured its first order for the RayCare oncology information system in China, alongside its RayStation treatment planning system, from the Shanghai Proton and Heavy Ion Center. The deal expands an existing relationship with the pioneering particle therapy provider and will support P-Cure’s newly installed proton therapy solution for upright treatment at the center.
The integrated RayStation and RayCare deployment gives SPHIC a unified software environment for treatment planning and oncology information management, underpinning its ambitions in advanced particle therapy. For RaySearch, the order marks a strategic milestone in driving global adoption of RayCare and strengthening its foothold in the fast-growing Chinese market for cutting-edge radiation therapy solutions.
More about RaySearch Laboratories AB
RaySearch Laboratories AB is a Swedish medical technology company specializing in software for advanced cancer treatment. Its portfolio includes the RayStation treatment planning system, the RayCare oncology information system, the RayIntelligence analytics platform and the RayCommand treatment control system, with products deployed at more than 1,200 clinics in 51 countries.
Average Trading Volume: 174,723
Technical Sentiment Signal: Buy
Current Market Cap: SEK7.54B
For an in-depth examination of RAY.B stock, go to TipRanks’ Overview page.